Jens Schreiner

Title: Jens Schreiner: Innovator in Cancer Therapy

Introduction

Jens Schreiner is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer therapy through his innovative work. With a total of 2 patents, Schreiner is recognized for his advancements in combination therapies that enhance the effectiveness of cancer treatments.

Latest Patents

Schreiner's latest patents focus on the development of combination therapies involving T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists. These inventions aim to improve cancer treatment outcomes by utilizing the synergistic effects of these therapeutic agents. The patents detail the mechanisms by which these combination therapies can activate T cells and inhibit cancer progression.

Career Highlights

Throughout his career, Jens Schreiner has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research in cancer therapies.

Collaborations

Some of his notable coworkers include Christian Klein and Vaios Karanikas. Their collaborative efforts have further advanced the research and development of innovative cancer treatments.

Conclusion

Jens Schreiner's work exemplifies the impact of innovation in the medical field, particularly in cancer therapy. His patents and collaborations highlight his commitment to improving patient outcomes through advanced therapeutic strategies.